Last reviewed · How we verify
Flt3L
At a glance
| Generic name | Flt3L |
|---|---|
| Also known as | CDX-301, Recombinant Human Flt3 Ligand |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors (PHASE1)
- In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors (PHASE1)
- CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer (PHASE1)
- FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer (PHASE2)
- Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy
- Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma (PHASE1)
- A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies (PHASE1)
- flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flt3L CI brief — competitive landscape report
- Flt3L updates RSS · CI watch RSS
- Icahn School of Medicine at Mount Sinai portfolio CI